Emerging Insulin Therapies for the Management of Type 2 Diabetes

Treatments for type 2 diabetes are rapidly emerging.

Recently, a team of investigators discussed various topics pertinent to advances in insulin for this patient population during HCPLive’s State of the Science event called New Advances in Insulin Therapy for the Management of Type 2 Diabetes.

A four-person panel, chaired by Serge Jabbour, MD, FACP, FACE, Sidney Kimmel Medical College at Thomas Jefferson University, discussed the type 2 diabetes landscape and the role of insulin therapy, patient communication and education insulin selection, and administration of emerging options, specifically insulin regular U500.

Joining Jabbour were Cheryl Marco RDN, LDN, CDCES, Barbara Simon, MD, and Eric Shiffrin, MD, all of Sidney Kimmel Medical College at Thomas Jefferson University.